

Gatien Moriceau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9050492/publications.pdf>

Version: 2024-02-01

13
papers

2,863
citations

759233

12
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

4629
citing authors

#	ARTICLE	IF	CITATIONS
1	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. <i>Cancer Discovery</i> , 2014, 4, 80-93.	9.4	836
2	Melanoma whole-exome sequencing identifies V600E-BRAF amplification-mediated acquired B-Raf inhibitor resistance. <i>Nature Communications</i> , 2012, 3, 724.	12.8	567
3	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. <i>Cell</i> , 2015, 162, 1271-1285.	28.9	516
4	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. <i>Cancer Cell</i> , 2015, 27, 240-256.	16.8	299
5	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. <i>Cancer Discovery</i> , 2014, 4, 69-79.	9.4	141
6	Recurrent Tumor Cell Intrinsic and Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. <i>Cancer Discovery</i> , 2017, 7, 1248-1265.	9.4	134
7	Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. <i>Journal of Translational Medicine</i> , 2015, 13, 210.	4.4	97
8	Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. <i>Cancer Discovery</i> , 2018, 8, 74-93.	9.4	89
9	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. <i>Cancer Cell</i> , 2021, 39, 1375-1387.e6.	16.8	78
10	Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. <i>Cancer Discovery</i> , 2021, 11, 714-735.	9.4	45
11	Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges. <i>Cancer Discovery</i> , 2022, 12, 1046-1069.	9.4	27
12	SPRED1 deletion confers resistance to MAPK inhibition in melanoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	19
13	Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. <i>Cancer Discovery</i> , 2022, 12, 1942-1959.	9.4	15